 | • レポートコード：MRC23Q36324 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、87ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の腎皮質壊死治療市場について調査・分析し、世界の腎皮質壊死治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（プレドニゾロン、アスピリン、炭酸水素ナトリウム、N-アセチルシステイン、スタチン、その他）、用途別セグメント分析（病院、がんクリニック、外来手術センター、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Allergan plc、Amgen Inc.、AstraZeneca plc、Baxter、Keryx Biopharmaceuticals, Inc、Teva Pharmaceutical Limited Inc、Pfizer、Novartis AG、Eisai Pharmaceuticals India Pvt. Ltd.などが含まれています。 世界の腎皮質壊死治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、腎皮質壊死治療市場規模を推定する際に考慮しました。本レポートは、腎皮質壊死治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、腎皮質壊死治療に関するビジネス上の意思決定に役立てることを目的としています。 ・腎皮質壊死治療市場の概要 - 腎皮質壊死治療のタイプ別セグメント - 世界の腎皮質壊死治療市場規模：タイプ別分析（プレドニゾロン、アスピリン、炭酸水素ナトリウム、N-アセチルシステイン、スタチン、その他） - 腎皮質壊死治療の用途別セグメント - 世界の腎皮質壊死治療市場規模：用途別分析（病院、がんクリニック、外来手術センター、その他） - 世界の腎皮質壊死治療市場規模予測（2018年-2029年） ・腎皮質壊死治療市場の成長トレンド - 腎皮質壊死治療の地域別市場規模（2018年-2029年） - 腎皮質壊死治療市場ダイナミクス - 腎皮質壊死治療の業界動向 - 腎皮質壊死治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：プレドニゾロン、アスピリン、炭酸水素ナトリウム、N-アセチルシステイン、スタチン、その他 - 世界の腎皮質壊死治療のタイプ別市場規模（2018年-2023年） - 世界の腎皮質壊死治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、がんクリニック、外来手術センター、その他 - 世界の腎皮質壊死治療の用途別市場規模（2018年-2023年） - 世界の腎皮質壊死治療の用途別市場規模（2024年-2029年） ・腎皮質壊死治療の地域別市場規模 - 北米の腎皮質壊死治療市場規模（2018年-2029年） - アメリカの腎皮質壊死治療市場規模（2018年-2029年） - ヨーロッパの腎皮質壊死治療市場規模（2018年-2029年） - アジア太平洋の腎皮質壊死治療市場規模（2018年-2029年） - 中国の腎皮質壊死治療市場規模（2018年-2029年） - 日本の腎皮質壊死治療市場規模（2018年-2029年） - 韓国の腎皮質壊死治療市場規模（2018年-2029年） - インドの腎皮質壊死治療市場規模（2018年-2029年） - オーストラリアの腎皮質壊死治療市場規模（2018年-2029年） - 中南米の腎皮質壊死治療市場規模（2018年-2029年） - 中東・アフリカの腎皮質壊死治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Allergan plc、Amgen Inc.、AstraZeneca plc、Baxter、Keryx Biopharmaceuticals, Inc、Teva Pharmaceutical Limited Inc、Pfizer、Novartis AG、Eisai Pharmaceuticals India Pvt. Ltd. ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Renal Cortical Necrosis Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Renal Cortical Necrosis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Renal Cortical Necrosis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Renal Cortical Necrosis Treatment in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Renal Cortical Necrosis Treatment include Allergan plc, Amgen Inc., AstraZeneca plc, Baxter, Keryx Biopharmaceuticals, Inc, Teva Pharmaceutical Limited Inc, Pfizer, Novartis AG and Eisai Pharmaceuticals India Pvt. Ltd., etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Renal Cortical Necrosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Renal Cortical Necrosis Treatment.
The Renal Cortical Necrosis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Renal Cortical Necrosis Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Renal Cortical Necrosis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Allergan plc
Amgen Inc.
AstraZeneca plc
Baxter
Keryx Biopharmaceuticals, Inc
Teva Pharmaceutical Limited Inc
Pfizer
Novartis AG
Eisai Pharmaceuticals India Pvt. Ltd.
Segment by Type
Prednisolone
Aspirin
Sodium Bicarbonates
N-acetyl Cysteine
Statins
Others
Segment by Application
Hospitals
Cancer clinics
Ambulatory Surgical Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Renal Cortical Necrosis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Renal Cortical Necrosis Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Prednisolone
1.2.3 Aspirin
1.2.4 Sodium Bicarbonates
1.2.5 N-acetyl Cysteine
1.2.6 Statins
1.2.7 Others
1.3 Market by Application
1.3.1 Global Renal Cortical Necrosis Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Cancer clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Renal Cortical Necrosis Treatment Market Perspective (2018-2029)
2.2 Renal Cortical Necrosis Treatment Growth Trends by Region
2.2.1 Global Renal Cortical Necrosis Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Renal Cortical Necrosis Treatment Historic Market Size by Region (2018-2023)
2.2.3 Renal Cortical Necrosis Treatment Forecasted Market Size by Region (2024-2029)
2.3 Renal Cortical Necrosis Treatment Market Dynamics
2.3.1 Renal Cortical Necrosis Treatment Industry Trends
2.3.2 Renal Cortical Necrosis Treatment Market Drivers
2.3.3 Renal Cortical Necrosis Treatment Market Challenges
2.3.4 Renal Cortical Necrosis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Renal Cortical Necrosis Treatment Players by Revenue
3.1.1 Global Top Renal Cortical Necrosis Treatment Players by Revenue (2018-2023)
3.1.2 Global Renal Cortical Necrosis Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Renal Cortical Necrosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Renal Cortical Necrosis Treatment Revenue
3.4 Global Renal Cortical Necrosis Treatment Market Concentration Ratio
3.4.1 Global Renal Cortical Necrosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Renal Cortical Necrosis Treatment Revenue in 2022
3.5 Renal Cortical Necrosis Treatment Key Players Head office and Area Served
3.6 Key Players Renal Cortical Necrosis Treatment Product Solution and Service
3.7 Date of Enter into Renal Cortical Necrosis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Renal Cortical Necrosis Treatment Breakdown Data by Type
4.1 Global Renal Cortical Necrosis Treatment Historic Market Size by Type (2018-2023)
4.2 Global Renal Cortical Necrosis Treatment Forecasted Market Size by Type (2024-2029)
5 Renal Cortical Necrosis Treatment Breakdown Data by Application
5.1 Global Renal Cortical Necrosis Treatment Historic Market Size by Application (2018-2023)
5.2 Global Renal Cortical Necrosis Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Renal Cortical Necrosis Treatment Market Size (2018-2029)
6.2 North America Renal Cortical Necrosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Renal Cortical Necrosis Treatment Market Size by Country (2018-2023)
6.4 North America Renal Cortical Necrosis Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Renal Cortical Necrosis Treatment Market Size (2018-2029)
7.2 Europe Renal Cortical Necrosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Renal Cortical Necrosis Treatment Market Size by Country (2018-2023)
7.4 Europe Renal Cortical Necrosis Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Renal Cortical Necrosis Treatment Market Size (2018-2029)
8.2 Asia-Pacific Renal Cortical Necrosis Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Renal Cortical Necrosis Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Renal Cortical Necrosis Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Renal Cortical Necrosis Treatment Market Size (2018-2029)
9.2 Latin America Renal Cortical Necrosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Renal Cortical Necrosis Treatment Market Size by Country (2018-2023)
9.4 Latin America Renal Cortical Necrosis Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Renal Cortical Necrosis Treatment Market Size (2018-2029)
10.2 Middle East & Africa Renal Cortical Necrosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Renal Cortical Necrosis Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Renal Cortical Necrosis Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan plc
11.1.1 Allergan plc Company Detail
11.1.2 Allergan plc Business Overview
11.1.3 Allergan plc Renal Cortical Necrosis Treatment Introduction
11.1.4 Allergan plc Revenue in Renal Cortical Necrosis Treatment Business (2018-2023)
11.1.5 Allergan plc Recent Development
11.2 Amgen Inc.
11.2.1 Amgen Inc. Company Detail
11.2.2 Amgen Inc. Business Overview
11.2.3 Amgen Inc. Renal Cortical Necrosis Treatment Introduction
11.2.4 Amgen Inc. Revenue in Renal Cortical Necrosis Treatment Business (2018-2023)
11.2.5 Amgen Inc. Recent Development
11.3 AstraZeneca plc
11.3.1 AstraZeneca plc Company Detail
11.3.2 AstraZeneca plc Business Overview
11.3.3 AstraZeneca plc Renal Cortical Necrosis Treatment Introduction
11.3.4 AstraZeneca plc Revenue in Renal Cortical Necrosis Treatment Business (2018-2023)
11.3.5 AstraZeneca plc Recent Development
11.4 Baxter
11.4.1 Baxter Company Detail
11.4.2 Baxter Business Overview
11.4.3 Baxter Renal Cortical Necrosis Treatment Introduction
11.4.4 Baxter Revenue in Renal Cortical Necrosis Treatment Business (2018-2023)
11.4.5 Baxter Recent Development
11.5 Keryx Biopharmaceuticals, Inc
11.5.1 Keryx Biopharmaceuticals, Inc Company Detail
11.5.2 Keryx Biopharmaceuticals, Inc Business Overview
11.5.3 Keryx Biopharmaceuticals, Inc Renal Cortical Necrosis Treatment Introduction
11.5.4 Keryx Biopharmaceuticals, Inc Revenue in Renal Cortical Necrosis Treatment Business (2018-2023)
11.5.5 Keryx Biopharmaceuticals, Inc Recent Development
11.6 Teva Pharmaceutical Limited Inc
11.6.1 Teva Pharmaceutical Limited Inc Company Detail
11.6.2 Teva Pharmaceutical Limited Inc Business Overview
11.6.3 Teva Pharmaceutical Limited Inc Renal Cortical Necrosis Treatment Introduction
11.6.4 Teva Pharmaceutical Limited Inc Revenue in Renal Cortical Necrosis Treatment Business (2018-2023)
11.6.5 Teva Pharmaceutical Limited Inc Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Renal Cortical Necrosis Treatment Introduction
11.7.4 Pfizer Revenue in Renal Cortical Necrosis Treatment Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 Novartis AG
11.8.1 Novartis AG Company Detail
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Renal Cortical Necrosis Treatment Introduction
11.8.4 Novartis AG Revenue in Renal Cortical Necrosis Treatment Business (2018-2023)
11.8.5 Novartis AG Recent Development
11.9 Eisai Pharmaceuticals India Pvt. Ltd.
11.9.1 Eisai Pharmaceuticals India Pvt. Ltd. Company Detail
11.9.2 Eisai Pharmaceuticals India Pvt. Ltd. Business Overview
11.9.3 Eisai Pharmaceuticals India Pvt. Ltd. Renal Cortical Necrosis Treatment Introduction
11.9.4 Eisai Pharmaceuticals India Pvt. Ltd. Revenue in Renal Cortical Necrosis Treatment Business (2018-2023)
11.9.5 Eisai Pharmaceuticals India Pvt. Ltd. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details